Twist Bioscience (TWST) Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY).

As part of the strategic partnership, Twist will provide antibody characterization data services for TuneLab. It will also provide data to support AbLab, an antibody developability prediction model, and high-throughput wet-lab data that can help train and improve those models.

Through the agreement, TuneLab users will be able to order Twist’s antibody services using preferred Twist protocols, generating wet-lab data that can support AI-enabled antibody discovery. The collaboration therefore gives Twist an opportunity to participate in the growing AI-enabled drug discovery ecosystem as a provider of experimental data and antibody characterization services.

The partnership could also create a potential avenue for incremental service revenue. TuneLab users will be able to order services from Twist, allowing the company to benefit if adoption of the platform translates into greater demand for antibody characterization and other experimental services.

Partnership Could Strengthen Twist’s Position in AI-Enabled Drug Discovery

Lilly’s selection of Twist Bioscience Corporation (NASDAQ:TWST) as an antibody characterization data provider could enhance the credibility of Twist’s antibody discovery and characterization capabilities. High-quality experimental data is increasingly important for developing and refining AI models used in drug discovery, potentially creating additional opportunities for companies capable of generating such datasets at scale.

The collaboration could consequently help Twist establish itself as an important data-generation and antibody-characterization layer within the broader AI-enabled drug discovery ecosystem. Importantly, Twist can potentially benefit from increasing AI adoption without assuming the substantial costs and risks associated with developing its own drug candidates.

Underlying Risks In Play

Despite the strategic potential, the TuneLab partnership does not provide significant near-term revenue visibility. The companies have not disclosed a minimum purchase commitment, contract value, or specific revenue guidance associated with the agreement.

Moreover, this is not a conventional drug development or commercialization partnership. The announcement does not disclose rights to Lilly drug candidates, milestone payments, royalties, or other participation in drug commercialization economics.

As a result, the financial opportunity for Twist will depend largely on the extent to which TuneLab users ultimately purchase its services.

There is also no guarantee that the rapid development of AI-driven drug discovery will translate into proportional revenue growth for experimental data providers. Although AI models require high-quality datasets, the ultimate commercial value of those datasets depends on whether the models can consistently generate viable drug candidates and improve the efficiency of drug development.

Hedge Fund Positioning and Short Interest

According to Insider Monkey’s database, the number of hedge funds holding Twist Bioscience Corporation (NASDAQ:TWST) increased to 42 in the second quarter from 30 in the first quarter. Among notable portfolio changes, Ark Investment Management reduced its position by 29% to $468.1 million. Farallon Capital increased its stake by 50% to $219.79 million, while DE Shaw significantly increased its position by 2,442% to $121.98 million.

Short interest has also declined. Shares sold short fell to 12.07 million as of August 31 from 14.08 million as of July 31. Nevertheless, short interest remained elevated at approximately 18.20%.

The Verdict

The Lilly TuneLab partnership strengthens Twist Bioscience Corporation (NASDAQ:TWST)’s exposure to the emerging intersection of AI and drug discovery. The company stands to benefit from increased demand for data to enhance drug development.

However, the near-term financial impact is unclear as the partnership does not include disclosed revenue commitments. Investors will therefore need to watch whether TuneLab adoption translates into meaningful demand for Twist’s services and whether the company’s broader AI-related partnerships ultimately contribute to sustainable revenue growth.

While we acknowledge the potential of TWST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures and Intel Corporation (INTC)’s Terafab Partnership Could Give Its AI Foundry Ambitions a Major Boost.

Disclosure: None. Follow Insider Monkey on Google News.